Physical capacity: the benchmark every longevity intervention should face.

Why capacity belongs at the centre

A longevity intervention should eventually help people do something, avoid an illness or survive longer. Physical capacity makes that demand concrete. A chair-rise test, a measured walking task or an exercise test can reveal whether an intervention changes the ability to function. These are not complete measures of ageing, but they set a useful standard for claims based only on molecular movement.

Fitness and survival: a large observational signal

Mandsager and colleagues analysed 122,007 adults referred for treadmill testing, with median follow-up of 8.4 years. Higher cardiorespiratory fitness was associated with lower mortality. This was an observational referral cohort, not a randomized comparison of training programmes. Existing illness, selection and other factors can influence the association. It cannot tell an individual how many years a particular VO₂ max improvement will add. [1]

The randomized result: mobility disability

The LIFE trial assigned 1,635 sedentary adults aged 70–89, with physical limitations, to structured activity or health education. Major mobility disability occurred in 30.1% versus 35.5% over an average of 2.6 years. The 5.4 percentage-point difference concerns disability in that population. It is not an absolute reduction in mortality or a result that applies unchanged to a healthy 30-year-old. [2]

What was studied?

LIFE combined supervised and home-based walking, resistance and flexibility activities. It tested a structured programme with support rather than one isolated exercise. This matters when comparing it with a capsule trial or an unsupervised routine. The treatment includes its delivery: attendance, progression and adaptation are part of the exposure. [2]

Strength, aerobic capacity and frailty answer different questions

A person can improve one capability while another remains limited. A useful assessment should name the task and the testing conditions, record change consistently and explain what would count as a meaningful difference. A wearable estimate is not identical to a laboratory exercise measurement. Nor does a high value on one test establish low risk in every organ system.

Ethernia’s suggested research lens is to ask what the measure captures, what it misses and whether it predicts or demonstrates an outcome. Avoid blending these into a proprietary “longevity score” whose components and trade-offs are hidden.

Why combination experiments matter

Arem’s pooled cohorts linked leisure-time activity to mortality, supporting the importance of movement as a research target. They do not establish that every experimental drug added to exercise improves the outcome. Combination claims require their own trials: a mechanism that seems beneficial in isolation may interact with adaptation, recovery or adherence. [3]

A fair standard for future interventions

Choose a prespecified functional endpoint, a suitable comparison group and enough follow-up to distinguish transient change from a durable improvement. Record injuries, dropout and whether improvements matter in daily life. For emerging treatments, evidence against this standard is more informative than an impressive pathway diagram alone. No current recruiting exercise trial is asserted here; the linked completed trials define useful designs and endpoints.

A functional outcome, in absolute terms

Major mobility disability in the LIFE trial over an average 2.6 years:

Both bars use a 0–100% scale. This is mobility disability, not mortality. LIFE study.